TNF and autoimmune disease: Adalimumab is a monoclonal antibody directed against tumor necrosis factor-α (TNF-α) and approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis and other autoimmune diseases (62).